BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang X, Yang C, Liao X, Han C, Yu T, Huang K, Yu L, Qin W, Zhu G, Su H, Liu X, Ye X, Chen B, Peng M, Peng T. NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma. Cancer Med 2017;6:2660-72. [PMID: 28960882 DOI: 10.1002/cam4.1202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Lim J, Kim MJ, Park Y, Ahn JW, Hwang SJ, Moon JS, Cho KG, Kwack K. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients. Sci Rep 2019;9:7895. [PMID: 31133717 DOI: 10.1038/s41598-019-44261-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kay C, Wang R, Kirkby M, Man SM. Molecular mechanisms activating the NAIP-NLRC4 inflammasome: Implications in infectious disease, autoinflammation, and cancer. Immunol Rev 2020;297:67-82. [PMID: 32729154 DOI: 10.1111/imr.12906] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
3 Wang X, Yang C, Liao X, Han C, Yu T, Huang K, Yu L, Qin W, Zhu G, Su H, Liu X, Ye X, Chen B, Peng M, Peng T. NLRC and NLRX gene family mRNA expression and prognostic value in hepatocellular carcinoma. Cancer Med 2017;6:2660-72. [PMID: 28960882 DOI: 10.1002/cam4.1202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
4 Wen J, Xuan B, Liu Y, Wang L, He L, Meng X, Zhou T, Wang Y. Updating the NLRC4 Inflammasome: from Bacterial Infections to Autoimmunity and Cancer. Front Immunol 2021;12:702527. [PMID: 34276697 DOI: 10.3389/fimmu.2021.702527] [Reference Citation Analysis]
5 Fan Z, Pan J, Wang H, Zhang Y. NOD-like receptor X1, tumor necrosis factor receptor-associated factor 6 and NF-κB are associated with clinicopathological characteristics in gastric cancer. Exp Ther Med 2021;21:208. [PMID: 33574909 DOI: 10.3892/etm.2021.9640] [Reference Citation Analysis]
6 Liu P, Lu Z, Liu L, Li R, Liang Z, Shen M, Xu H, Ren D, Ji M, Yuan S, Shang D, Zhang Y, Liu H, Tu Z. NOD-like receptor signaling in inflammation-associated cancers: From functions to targeted therapies. Phytomedicine 2019;64:152925. [PMID: 31465982 DOI: 10.1016/j.phymed.2019.152925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
7 Pickering RJ, Booty LM. NLR in eXile: Emerging roles of NLRX1 in immunity and human disease. Immunology 2021;162:268-80. [PMID: 33314068 DOI: 10.1111/imm.13291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Wang X, Liao X, Huang K, Zeng X, Liu Z, Zhou X, Yu T, Yang C, Yu L, Wang Q, Han C, Zhu G, Ye X, Peng T. Clustered microRNAs hsa-miR-221-3p/hsa-miR-222-3p and their targeted genes might be prognostic predictors for hepatocellular carcinoma. J Cancer 2019;10:2520-33. [PMID: 31258758 DOI: 10.7150/jca.29207] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
9 Nagai-Singer MA, Morrison HA, Allen IC. NLRX1 Is a Multifaceted and Enigmatic Regulator of Immune System Function. Front Immunol. 2019;10:2419. [PMID: 31681307 DOI: 10.3389/fimmu.2019.02419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
10 Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi GM, Shen YH, Cai JB, Yang Z, Zhou J, Fan J, Sun HC, Kuang M, Huang C. NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells. J Hematol Oncol 2018;11:28. [PMID: 29482578 DOI: 10.1186/s13045-018-0573-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
11 Yan M, Jing X, Liu Y, Cui X. Screening and identification of key biomarkers in bladder carcinoma: Evidence from bioinformatics analysis. Oncol Lett 2018;16:3092-100. [PMID: 30127900 DOI: 10.3892/ol.2018.9002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]